IL17A and hematocrit: As such, the present study aimed to measure serum levels of sTWEAK and of IL-17A in patients with primary HT -with/without AOD- as well as to determine the relationship between the serum sTWEAK and IL17-A levels, and such markers of AOD as carotid intima media thickness (CIMT), proteinuria, retinopathy, and the left ventricular mass index (LVMI).